Ovid Therapeutics Inc. (NASDAQ:OVID) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ovid Therapeutics Inc.||2||0.00||N/A||-2.03||0.00|
|Sarepta Therapeutics Inc.||131||26.66||N/A||-5.94||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for Ovid Therapeutics Inc. and Sarepta Therapeutics Inc.
Table 2 provides Ovid Therapeutics Inc. and Sarepta Therapeutics Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Ovid Therapeutics Inc.||0.00%||0%||0%|
|Sarepta Therapeutics Inc.||0.00%||-43.4%||-26.7%|
Ovid Therapeutics Inc. has a Current Ratio of 7.8 and a Quick Ratio of 7.8. Competitively, Sarepta Therapeutics Inc.’s Current Ratio is 12.2 and has 11.1 Quick Ratio. Sarepta Therapeutics Inc.’s better ability to pay short and long-term obligations than Ovid Therapeutics Inc.
The following table delivered below contains the ratings and recommendations for Ovid Therapeutics Inc. and Sarepta Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ovid Therapeutics Inc.||0||0||0||0.00|
|Sarepta Therapeutics Inc.||0||0||15||3.00|
On the other hand, Sarepta Therapeutics Inc.’s potential upside is 64.71% and its average target price is $203.56.
Insider and Institutional Ownership
The shares of both Ovid Therapeutics Inc. and Sarepta Therapeutics Inc. are owned by institutional investors at 31.8% and 95.9% respectively. Ovid Therapeutics Inc.’s share held by insiders are 12.1%. Comparatively, Sarepta Therapeutics Inc. has 0.3% of it’s share held by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ovid Therapeutics Inc.||-7.27%||-11.69%||10.27%||-36.05%||-79.86%||-15.7%|
|Sarepta Therapeutics Inc.||-0.37%||-4.95%||28.76%||14.56%||29.09%||36.4%|
For the past year Ovid Therapeutics Inc. had bearish trend while Sarepta Therapeutics Inc. had bullish trend.
Sarepta Therapeutics Inc. beats Ovid Therapeutics Inc. on 5 of the 8 factors.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is based in New York, New York.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.